Amyotrophic Lateral Sclerosis; Clinical Phenotypes and Heritability {#S1}
===================================================================

Amyotrophic lateral sclerosis (ALS) is a devastating progressive neurodegenerative disorder characterized by the loss of lower and upper motor neurons, resulting in paralysis of the limb, bulbar and respiratory muscles, and is typically fatal within 3--5 years from disease onset ([@B88]). The disease incidence is ∼2 per 100,000 population and it is projected that rates of ALS will increase from ∼222,000 worldwide in 2015 to ∼376,000 in 2040 ([@B12]). In addition to the growing financial burden of this disease, there is a significant burden on the patients' families and carers. As such, it is critical to improve our understanding of how genetic mechanisms may contribute to the pathogenesis of this devastating disease. Investigation of short structural variations (SVs) in known ALS genes has multiple potential objectives, and may help to uncover some of the missing heritability in sporadic ALS. Characterization of short SVs may inform the discovery of novel disease mechanisms and therapeutic targets, and be useful for stratification of patient subgroups in clinical trials.

ALS is a heterogeneous disease, with variable clinical presentation between patients, and is characterized by progressive motor deficits that evolve over weeks or months, eventually affecting most voluntary muscles in the body ([@B109]). The heterogeneity of clinical presentation and diverse rates of progression make the disease challenging to diagnose, and there is currently no definitive diagnostic test. As a result, it is usually characterized on the basis of the site and pattern of onset, and the degree of involvement of upper and lower motor neurons, and can be classified into the following categories: (i) progressive bulbar palsy (difficulty swallowing and speech disturbances); (ii) limb-onset ALS; (iii) progressive muscular atrophy (involving only lower motor neurons); and (iv) upper motor neuron predominant ALS ([@B62]). Most commonly, individuals will present with asymmetrical focal weakness of the extremities (poor hand grip, foot drop, stumbling) or bulbar characteristics (dysarthria and dysphagia). Other typical symptoms include muscle fasciculation, cramps and hyperreflexia in regions of atrophy, without accompanying sensory disturbances ([@B62]). Importantly, the different clinical phenotypes exhibit differing rates of progression, with the bulbar-onset form having the most rapid progression and shortest survival time ([@B82]). In addition, there is considerable variability between cases within the same diagnostic category. Given the degree of heterogeneity, it remains to be determined whether the different clinical phenotypes all represent variations of the same disease, or whether there is also heterogeneity in the underlying genetic and molecular disease determinants. At present, there is a lack of specific genetic or other biomarkers for the different disease subtypes, or indicators of disease trajectory in well-documented patient cohorts.

Approximately 10% of ALS cases are classed as familial (fALS), while the remainder, with no prior family involvement, are classified as having the sporadic form of the disease (sALS) ([@B86]). Since the landmark discovery of the first mutation in the superoxide dismutase 1 gene *(SOD1)* in fALS in the early 1990s ([@B90]), there has since been significant progress in understanding of the genetics of the familial disease, with approximately 70% of the genetic mutations that contribute to fALS having been identified ([@B27]). However the genetic underpinnings of sporadic ALS (sALS) remain a formidable challenge ([@B6]; [@B86]). Comparatively, few mutations have been described for sALS, despite the application of high throughput genetic analysis methods ([@B79]). These methodologies have failed to identify disease-associated genetic variations in the majority of sALS patients, highlighting the complexity and genetic heterogeneity contributing to this disease phenotype. Approximately 10% of sALS cases can be explained by mutations in 25 known ALS-linked genes, with the remaining 90% of cases as yet having an undetermined genetic contributor ([@B11]; [@B86]; [@B36]). At a glance these data may imply that the genetic contributions to sALS are minor, however, heritability estimates and twin studies suggest a genetic contribution of up to 65% ([@B4]; [@B8]). It is therefore likely that additional genetic contributors to sALS risk remain to be identified. The situation may be analogous to that for Alzheimer's disease where the *APOE* ε4 (Apolipoprotein E) risk allele has a frequency of only 14% and does not fully explain the Alzheimer's disease age-of-onset risk ([@B30]; [@B93]). However, after discovery of the structural variant (rs10524523) in the neighboring *TOMM40* (Translocase of outer mitochondrial membrane 40) gene, age of onset risk could now be assessed for \>90% of the at risk population ([@B92]).

Currently there are only two therapeutics available for the treatment of ALS, Riluzole (approved in Australia, United States, and Europe) and Edaravone (approved in Japan, South Korea, and United States) ([@B95]) that impact excitotoxicity ([@B37]) or anti-oxidant pathways ([@B95]), respectively and may slow disease progression for a relatively short period of time. However, these drugs are only effective in some patients and there is currently no way to determine those most likely to respond to the drugs. For the patients that do show a response, life is only prolonged by approximately 3 months. Further understanding of ALS pathogenesis should inform the development of more effective therapies and help identify patients likely to respond to specific treatments.

Genetic Characterization and Genome-Wide Association Studies {#S2}
============================================================

Genome wide association studies analysing single nucleotide polymorphisms (SNP) and whole exome sequencing studies have provided a wealth of information relating to common variants associated with a range of diseases. Despite this, such approaches have generally identified genes that are either inherited in fALS, those that are weakly associated with sALS, or mutations associated with rare forms of the disease ([@B86]). Some of the ALS genes identified by these techniques include *UNC13A, C9orf72, DPP6, ELP3*, *KIFAP3, TBK1, CHCHD10, TUBA4A, CCNF, MATR3, NEK1, C21orf2, ANXA11*, and *TIA1* (see [Table 1](#T1){ref-type="table"}; [@B11]; [@B79]). A major issue with utilizing these technologies is that by testing thousands of SNPs across the genome, low effect size associations are generated for numerous gene regions, inevitably leading to very high thresholds of significance for potentially weak genetic effects ([@B91]). This can lead to false positive associations or a lack of reproducibility between different populations that have rarely translated into tools for clinical trial patient stratifications, with the exception of *UNC13A* (see below). The amount of information these techniques can provide regarding complex disease and the functional outcomes of SNPs are limited. Particularly, these methods have not been able to account for the variation in age-of-onset and progression in ALS patients ([@B5]), and fail to explain the missing heritability of the disease ([@B7]; [@B71]). Whole genome sequencing can examine the entirety of the genome to better capture larger scale variations, as opposed to single nucleotide changes, however, these methods come with their own technical limitations; high throughput short-read sequencing technologies are unable to accurately capture these regions due to amplification stutter, and misaligning of the short-read sequences, often misrepresenting their true variability ([@B17]). Recently, it was demonstrated that variable areas of the genome can camouflage each other, particularly where short-read DNA sequences map equally well to different loci, resulting in poor SV characterization ([@B39]). To date, these techniques have only accounted for the genetic cause of approximately 10% of sALS cases ([@B27]). Therefore, it is essential to rethink the approach and acknowledge the limitations of these technologies when interrogating the genome. Specifically, there are vast regions of genetic variability yet to be uncovered in non-coding regions, which might have significant implications in the context of complex disease.

###### 

This table lists published genes that have been associated with ALS and highlights the discovery method for each gene as well as the gene function.

  ALS genes      Discovery method         Gene function                                       References   Number of predicted short SVs
  -------------- ------------------------ --------------------------------------------------- ------------ -------------------------------
  *C9orf72*      GWAS                     RNA metabolism                                      [@B77]       31
  *TARDP*        Candidate gene linkage   RNA metabolism                                      [@B47]       63
  *FUS*          Candidate gene linkage   RNA metabolism                                      [@B119]      45
  *MATR3*        WES                      RNA metabolism                                      [@B57]       60
  *TIA1*         WES                      RNA metabolism                                      [@B24]       83
  *HNRNPA1*      Linkage WES              RNA metabolism                                      [@B61]       23
  *HNRNPA2/B1*   Linkage WES              RNA metabolism                                      [@B61]       24
  *EWSR1*        Candidate gene           RNA metabolism                                      [@B31]       66
  *TAF15*        Candidate gene           RNA metabolism                                      [@B110]      35
  *ANG*          Candidate gene           RNA metabolism                                      [@B50]       25
  *SMN1*         Candidate gene           Interaction with RNA binding proteins               [@B29]       68
  *ELP3*         GWAS                     Transcript elongation                               [@B101]      62
  *SETX*         Linkage                  DNA/RNA processing                                  [@B20]       101
  *SPG11*        Linkage                  DNA damage                                          [@B83]       110
  *APEX1*        Candidate gene           Endonuclease                                        [@B49]       13
  *UBQLN2*       Candidate gene linkage   Protein quality control                             [@B34]       9
  *VCP*          Candidate gene           Protein quality control                             [@B56]       37
  *OPTN*         Homozygosity mapping     Protein quality control                             [@B70]       54
  *VAPB*         Linkage                  Protein quality control                             [@B81]       64
  *TBK1*         WES                      Protein quality control                             [@B46]       59
  *SQSTM1*       Candidate gene           Protein quality control                             [@B42]       38
  *CCNF*         Genome wide linkage      Protein quality control                             [@B123]      48
  *PFN1*         Linkage WES              Cytoskeletal and trafficking                        [@B124]      21
  *TUBA4A*       WES                      Cytoskeletal and trafficking                        [@B103]      24
  *KIF5A*        GWAS                     Cytoskeletal and trafficking                        [@B80]       52
  *ANXA11*       WES                      Cytoskeletal and trafficking                        [@B104]      41
  *NEFH*         Candidate gene           Cytoskeletal and trafficking                        [@B44]       43
  *DCTN1*        Candidate gene           Cytoskeletal and trafficking                        [@B78]       18
  *PRPH*         Candidate gene           Cytoskeletal protein                                [@B66]       50
  *FIG4*         Candidate gene           Cytoskeletal organization and vesicle trafficking   [@B23]       66
  *CFAP410*      GWAS                     Cytoskeletal and DNA damage response                [@B118]      15
  *KIFAP3*       GWAS                     Kinesin associated protein                          [@B64]       55
  *ALS2*         Linkage                  Endosomal dynamics                                  [@B52]       69
  *SIGMAR1*      Homozygosity mapping     Endoplasmic reticulum chaperone                     [@B10]       21
  *SOD1*         Linkage                  Mitochondrial dysfunction and oxidative stress      [@B90]       30
  *CHCHD10*      Candidate gene           Mitochondrial dysfunction and oxidative stress      [@B14]       32
  *NEK1*         WES                      Mitochondrial dysfunction and oxidative stress      [@B59]       99
  *ATXN2*        Candidate gene           Endocytosis, cell survival                          [@B40]       186
  *GRN*          Candidate gene           Cell growth regulator                               [@B97]       34
  *UNC13A*       GWAS                     Neurotransmitter release                            [@B117]      103
  *PLCD1*        GWAS                     Signal transduction                                 [@B107]      21
  *CHMP2B*       Candidate gene           Recycling of cell receptors                         [@B84]       22
  *ITPR2*        GWAS                     Receptor                                            [@B115]      204
  *ARHGEF28*     Candidate gene           Nucleotide exchange factor                          [@B38]       138
  *DAO*          Candidate gene           Potential detoxifying agent                         [@B74]       52
  *DPP6*         GWAS                     Modifies calcium gated channels                     [@B116]      235
  *VEGFA*        Candidate gene           Angiogenesis, migration of endothelial cells        [@B63]       15
  *HFE*          Candidate gene           Iron absorption                                     [@B122]      31
  *PON1*         Candidate gene           Organophosphate hydrolysis                          [@B102]      24

Using the method described by

Saul et al. (2016)

we have predicted the number of short structural variants in each gene that may warrant further investigation. This does not include insertion/deletions or SNPs.

Structural Variants {#S3}
===================

Structural variants (SVs) are defined as insertions, deletions, inversions and microsatellites that can be repeated hundreds of times. SVs predominantly occur in non-coding regions of the genome and often do not change the composition of the mature protein ([@B93]). Despite this, changes in the size and composition of SVs can have a significant impact on the regulatory elements that modulate gene expression ([@B21]). Therefore, SVs can potentially provide a deeper understanding of how gene expression in complex genetic disease can affect disease etiology, duration, progression and patient outcomes ([@B43]). SVs have been implicated in many complex diseases including retinitis pigmentosa (*MSR1*) ([@B89]), Alzheimer's (*TOMM40*) ([@B68]), frontotemporal dementia (*C9orf72*) ([@B33]; [@B87]), and other neurodegenerative diseases ([@B15]).

The ability of SVs to alter gene expression is likely dependent on their location within and around the gene or intergenic region, with their effects occurring via several mechanisms including, influencing the binding of regulatory elements that determine transcription, mRNA splicing and processing, genome folding and higher order structure, and translation ([@B93]). This may differentiate mechanisms of disease pathogenesis, including risk of disease, risk for a specific phenotype, symptom presentation, disease course and response to treatment, between individuals ([Figure 1A](#F1){ref-type="fig"}). Due to the variable nature, as well as the repeat structure of SVs, many remain poorly characterized by analysis platforms such as next generation sequencing ([@B17]; [@B39]).

![**(A)** Schematic representing potential regulation of gene expression by structural variants and possible effects on disease characteristics. **(B)** Example of an under-characterized gene from the NCBI database GRch38.p13 primary assembly, a region that has been repeatedly mapped but lacks consensus around the nature of this repeat sequence and its true variability. The reference sequence is located at the top of the image, the purple bars depict a sequencing entry with variable size and its associated rs number and red bars represent a SNP entry (Gene \[Internet\]. Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information; 2004 -- \[cited 2019 September 24\]. Available from: <https://www.ncbi.nlm.nih.gov/gene/>).](fnins-14-00047-g001){#F1}

Historically, research on SVs has focused on genomic elements that are larger in size (\>1 kb) and much easier to capture by high throughput techniques, such as copy number variations, transposable elements, larger insertion/deletions, translocations, and duplications ([@B99]; [@B43]; [@B53]; [@B9]; [@B108]); yet other small variable regions of the genome remain under characterized and are more difficult to capture with short-read sequencing techniques ([Figure 1B](#F1){ref-type="fig"}; [@B19]; [@B39]). Recently, a comprehensive review highlighted the strengths and weakness of various sequencing methods and bioinformatics tools used for SV calling, and the difficulties in capturing smaller novel variations ([@B69]). In addition, comparing the accuracy of SV characterization between methodologies when different *in silico* data sets are often utilized remains a challenge ([@B69]). Furthermore, how these methods translate and generalize to patient samples is unclear, making it critical to establish standard procedures and bench-marks for the interpretation of SV data. There is a growing need to utilize SV information in the clinical setting to inform variation in patient phenotypes. Therefore we and others believe, important genes that may be critical to understanding the variation between patients that cannot be fully explained by SNPs or other mutations, should be reinvestigated for short SVs. Unrecognized or under characterized SVs could influence the expression of these genes, thereby contributing to the risk of ALS.

Recent studies investigating the transcriptome of the spinal cord anterior horn have identified significantly different RNA profiles between ALS patients and controls, for a multitude of gene pathways ([@B35]). Since SVs can exhibit a range of regulatory effects that can impact levels of gene expression and potentially the phenotype, it is essential that these regions are also properly characterized. For example, a microsatellite repeat element in the promotor region of *PRPF31* (precursor mRNA-processing factor 31) results in some mutation carriers developing retinitis pigmentosa, whilst others remain asymptomatic ([@B89]). The length of this SV was shown to impact the penetrance of the mutation by suppressing transcription of this region by 50--115-fold, resulting in haploinsufficiency ([@B89]). Such disease mechanisms also warrant investigation in ALS.

STRUCTURAL VARIANTS IN ALS: *C9orf72* AND *ATXN2* VARIATION {#S3.SS1}
-----------------------------------------------------------

An example of an SV that results in ALS pathogenesis is the repeat expansion in the *C9orf72* gene. The protein encoded by this gene is thought to play a role in endosomal membrane trafficking and autophagy ([@B41]). The SV region of *C9orf72* is a hexanucleotide repeat located in intron 1, GGGGCC that is usually repeated up to 30 times in healthy individuals. Expansion of this repeat to hundreds or thousands of repeated segments is a recognized cause of fALS, frontotemporal dementia, and occasionally also sALS ([@B73]). The DNA encoding this repeat is transcribed bi-directionally, resulting in nuclear RNA inclusions, and is thought to promote gain of function toxicity ([@B67]; [@B106]). Other potential mechanisms include *C9orf72* loss of function ([@B100]; [@B106]), or proteotoxicity ([@B48]). In particular, patients with expanded repeats have a more severe phenotype, are predominantly bulbar onset, exhibit an earlier age of disease onset, cognitive and behavioral impairment and reduced survival ([@B16]; [@B28]). In addition, microsatellite repeats are subjected to an unconventional mechanism called repeat associated non-ATG (RAN) translation ([@B126]), whereby proteins can be coded by the additional two reading frames (GCA and AGC) resulting in up to six dipeptide proteins ([@B25], [@B26]). The accumulation of these dipeptide proteins is seen in the central nervous system of individuals with ALS and contributes to a multitude of mechanisms that can induce protein-mediated toxicity ([@B13]). One of the current strategies employed in the development of therapeutics for *C9orf72* is to target the SV region with antisense oligonucleotides to induce transcript degradation by RNase H enzymatic cleavage, preventing the build-up of toxic *C9orf72* transcript and protein. Other strategies focus on modulating the expression of transcription factors specifically involved in transcribing expanded repeats ([@B67]). Recently, it was shown that small ribosomal subunit protein (RPS25) plays a direct role in RAN translation, and decreasing its levels through RNA interface mediated reduction prolonged the lifespan of *Drosophila* with the expanded repeat ([@B125]). In addition, antisense oligonucleotide targeting of RPS25 enhanced the survival of *C9orf72* derived motor neurons reducing poly-GR and poly-PR foci ([@B125]). The recent identification of a RAN translation regulator is a big step forward in demonstrating the functional implications of SV repeats in disease, and indicates antisense oligonucleotide or small molecules could be a viable therapeutic option for targeting RPS25 for patients with *C9orf72* ([@B54]). However, further research is needed to understand the regulation of expanded repeats and determine the relative contribution of repeat RNA and dipeptide repeat proteins to patient phenotype and cellular toxicity that promotes neurodegeneration in ALS.

Another SV contributing to ALS pathogenesis occurs in the gene encoding ataxin-2 (*ATXN2)*. *ATXN2* contains a CAG repeat, initially found to be associated with a class of neuromuscular and neurological disorders, known as polyglutamine disorders, caused by the expansion of the microsatellite repeat within the coding sequence ([@B6]; [@B65]). The ATXN2 protein is involved in endocytosis and modulates mTOR signals, critical to maintaining cell growth and survival, thereby modifying translation and mitochondrial function ([@B18]). The N-terminal of this protein contains a polyglutamine tract that generally consists of 14--31 residues that when expanded, can carry up to 200 residues in the pathogenic state ([@B105]). Long expanded repeats were initially found to cause spinocerebellar ataxia 2 and subsequently, intermediate length repeats were shown to increase the risk of developing ALS ([@B32]; [@B112]), with one study demonstrating that ALS risk increases exponentially with repeat length until the cut-off for developing spinocerebellar ataxia is reached ([@B105]). The polyglutamine disease causing mechanism differs between conditions and may include a loss of function resulting from hyper-methylation ([@B55]), a toxic gain of function through RAN translation ([@B98]), protein misfolding and aggregation ([@B58]), and in ALS, increasing TDP-43 toxicity ([@B40]). Longer repeats were expected to result in increased toxic TDP-43 build-up, resulting in increased risk of disease, an earlier age of onset and faster progression, however, this is not necessarily seen in patients ([@B5]). The possibility of oligogenic inheritance is the likely explanation, where multiple risk factors from polymorphic structural variants are required to act together over time, with environmental stressors, to cause the development of ALS ([@B3]), accounting for the particular variability seen in age-of-onset and disease progression. A better understanding of these variable regions of the genome and how they might work together to cumulatively increase disease risk, resulting in motor neuron dysfunction and susceptibility to neuronal degeneration, is imperative.

Therapeutic Development Challenges {#S4}
==================================

Over the past 20 years, more than 50 controlled trials of putative ALS therapeutics, testing 60 molecules have failed to demonstrate clinical efficacy ([@B85]). Transgenic *SOD1* mice have been used for the majority of ALS pre-clinical drug development studies; however, these models do not translate well to human disease ([@B75]). Alternative approaches need to be used to evaluate the potential efficacy of compounds. Identification and utilization of genetic markers, such as SVs informative for ALS, could be incorporated into clinical trial design to reduce the participant heterogeneity ([@B113]).

Poor understanding of the pathogenic mechanisms of ALS neuro-degeneration remains a barrier to the development of novel therapeutic approaches. Moreover, there are few biomarkers that allow patient stratification according to disease mechanism ([@B1]; [@B60]; [@B76]; [@B120]). As a result, efficacy can only be evaluated by clinical measures during clinical trials ([@B75]; [@B76]). Clearly, there is a critical unmet need to establish well-characterized molecular biomarkers that can be used as therapeutic targets, or to inform on the validity of certain treatment approaches. As ALS is a complex, heterogenous disorder with a varied age of onset and expression, it is likely that no single therapeutic will be effective for all patients. Therefore, we must develop strategies to identify patient subgroups and develop compounds to address the specific molecular defect.

Establishing molecular targets and markers for ALS could lead to improved patient stratification for clinical trials, to enable treatment effects to be identified within specific patient sub-groups. An example of the success of this approach is provided by clinical research with lithium carbonate in ALS patients. After a pilot study demonstrated attenuation of disease progression in a small number of ALS patients treated with lithium carbonate ([@B45]), a number of follow up clinical studies have failed to replicate the finding ([@B2]; [@B22]; [@B72]; [@B121]; [@B111]). In a meta-analysis of three trials that failed to show a significant effect of lithium treatment in ALS, [@B114] retrospectively demonstrated that lithium-treated patients who carried the *UNC13A* (C/C) genotype had a slower disease trajectory and showed a 70% improvement in 12 month survival, whilst carriers of the same genotype receiving no treatment had significantly reduced survival trajectories ([@B114]). This survival benefit was only evident once the patients were stratified by their genotype, as the heterogeneous trial cohort originally masked the identification of any therapeutic benefit for a subgroup. In a more recent report [@B113] demonstrated that different genotypes including the repeat expansion *C9orf72* can interact with both primary and secondary endpoints of clinical trials. Interestingly, in this report *C9orf72* carriers did not have reduced survival, however, they did exhibit an accelerated monthly decline measured by ALSFRS compared to non-carriers. No pharmacogenetic interactions were demonstrated in the valproic acid trial, however, there was a pharmacognetic interaction between creatine treatment and the A allele of *MOBP*, whilst a dose response was observed for the C allele of *UNC13A* improving survival outcomes ([@B113]). This highlights the importance of taking genetic information into account in clinical trials to enrich trial populations for potential responders. Identifying new genetic variations that may explain changes in gene expression in sALS patients will therefore be extremely useful to help inform both primary and secondary end points in clinical trial, and may improve the likelihood of clinical trial success.

Concluding Remarks {#S5}
==================

The methodologies currently used to elucidate ALS pathogenesis and inform drug development have not delivered effective therapeutic strategies to date. In our view, continuing to perform further genome wide association studies is unlikely to provide the breakthroughs that are urgently needed. Genome wide studies can sometimes identify biochemical pathways involved in disease and indicate genes associated with fALS and sALS, however, in-depth characterization of these implicated regions may identify SVs that influence ALS susceptibility. Limitations of GWAS and even whole genome sequencing in identifying ALS risk must be recognized, since allele frequencies of variants or SNPs may not differ between patient cohorts and controls in these complex diseases. With increasing likelihood that SVs do indeed contribute to ALS risk, future investigations will need to incorporate SVs into genetic studies. It is possible that a combination of variants occurring frequently throughout healthy populations will collectively contribute to the vulnerability of motor neurons, and that this could be further exacerbated by both physiological and environmental insults. Particular SVs may better account for the variability in phenotypes and progression across ALS patient cohorts, and could be critical targets that can inform drug development. As our current molecular understanding of ALS has proven largely ineffective in easing the burden of ALS, clinical trials are likely to continue to fail if analyses are restricted to conventional strategies and platforms.

*In silico* investigations by our laboratory group reveal that there are a number of under-characterized genomic regions in ALS genes. Genetic data-bases including National Center for Biotechnology Information^[1](#footnote1){ref-type="fn"}^, Ensembl genome browser 97^[2](#footnote2){ref-type="fn"}^ and University of California Santa Cruz genome browser^[3](#footnote3){ref-type="fn"}^ have multiple sequence entries logged for genomic loci under different RS numbers. Sequencing technologies, whilst sometimes precise, have limited accuracy ([@B91]), as they only provide the location but not the specifics of each variant in individual patients. These poorly characterized regions of the genome could therefore contribute to the missing heritability of ALS. In most cases, the variation in allele length and allele frequency remains unclear, ultimately leading to the question, "how significant a role do SVs play in complex diseases, such as ALS?" We have focused on the development of accurate assays to genotype SVs. For example, investigation of the *SOD1* region has led to the characterization of SV1, a variant located within the 3′ untranslated region of *SCAF4*, a downstream gene that was previously overlooked. The function of *SCAF4* has recently been elucidated, with the protein being necessary for accurate termination of transcription by ensuring correct polyadenylation site selection ([@B51]). This SV appears to influence *SOD1* expression, possibly through a toxic gain of function, and could more broadly influence ALS pathogenesis ([@B94]). Continued investigations into the function of SV1 are presently underway in our laboratory. In addition, other variants appear to stratify sALS patients on the basis of survival and may in fact act as modifiers of gene expression (unpublished data). If this data is confirmed, it will not only indicate novel mechanisms contributing to ALS, but also allow patient stratification for enrichment of ALS clinical trials. Although SVs may not always be a viable drug target, they may indicate pathways that can be targeted to inform drug development. It is our belief that we need to re-assess these regions of the genome in order to identify some of the missing heritability of ALS and explain the phenotypic variability seen across this disease.
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